Management of Borderline Resectable NSCLC

EP: 1.Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

EP: 2.Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

EP: 3.Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC

EP: 4.Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC

Now Viewing

EP: 5.Management of Borderline Resectable NSCLC

EP: 6.Management of Resectable Early Stage NSCLC with Actionable Mutations

EP: 7.Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

EP: 8.Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease

EP: 9.Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

EP: 10.Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

Video content above is prompted by the following:

In patients deemed borderline resectable, do you re-assess for resectability after neoadjuvant chemoimmunotherapy?

• How do you manage patients who do not undergo surgery after neoadjuvant chemoimmunotherapy?
• How do you managepatientswho do not achieve a pCR or an MPR after neoadjuvant chemo-IO?

How do you manage patients who do not achieve a pCR or an MPR after neoadjuvant